<p>Van Hulzen Asset Management LLC 在最近向證券交易委員會的披露中表示，在第一季度減少了對強生（NYSE:JNJ - 免費報告）22.5% 的持股。該公司在此期間出售了 34,558 股後，持有 118,842 股強生的股票。強生約佔 Van Hulzen Asset Management LLC 投資組合的 1.8%，使其成為該公司第 12 大持倉。截止最近一個季度末，Van Hulzen Asset Management LLC 在強生的持股價值為 19,709,000 美元。</p>
<ul>
<li>JNJ 股票上漲表明對新增長路徑的信心</li>
</ul>
<p>其他大型投資者最近也買賣了該公司的股票。Brighton Jones LLC 在第四季度將其在強生的股份增加了 13.9%。Brighton Jones LLC 現在持有 51,876 股強生的股票，價值 7,502,000 美元，此前在此期間又購買了 6,332 股。Hudson Value Partners LLC 在第四季度將其在強生的股份增加了 2.5%。Hudson Value Partners LLC 現在持有 41,403 股強生的股票，價值 5,648,000 美元，此前在上個季度又收購了 1,022 股。Burling Wealth Partners LLC 在第四季度收購了強生的新股份，價值為 3,908,000 美元。Integrated Wealth Concepts LLC 在第四季度將其在強生的股份增加了 6.1%。Integrated Wealth Concepts LLC 現在持有 108,473 股強生的股票，價值 15,687,000 美元，此前在上個季度又購買了 6,247 股。最後，Empire Financial Management Company LLC 在第四季度將其在強生的持倉增加了 18.0%。Empire Financial Management Company LLC 現在持有 17,882 股強生的股票，價值 2,586,000 美元，此前在上個季度又購買了 2,732 股。69.55% 的股票由機構投資者和對沖基金持有。</p>
<p>獲取 <strong>強生</strong> 的提醒：</p>
<h2>強生股票表現</h2>
<p>強生的股票在週五開盤價為 178.8990 美元。強生的 12 個月低點為 140.68 美元，12 個月高點為 180.61 美元。該公司的 50 日移動平均線為 163.04 美元，200 日移動平均線為 159.05 美元。該公司的速動比率為 0.76，流動比率為 1.01，債務與股本比率為 0.50。該公司的市值為 4308.5 億美元，市盈率為 19.13，市盈增長比率為 2.28，貝塔值為 0.41。</p>
<ul>
<li>3 大強勁收益的高分紅股票</li>
</ul>
<p>強生（NYSE:JNJ - 獲取免費報告）最近一次發佈財報是在 7 月 16 日，報告每股收益（EPS）為 2.77 美元，超出分析師一致預期的 2.68 美元，超出 0.09 美元。強生的淨利潤率為 25.00%，股本回報率為 32.49%。該公司在本季度的收入為 237.4 億美元，而分析師預期為 228.5 億美元。去年同期，該公司每股收益為 2.82 美元。強生的收入同比增長 5.8%。強生已將 2025 財年的指引設定為每股收益 10.800-10.900 美元。股票分析師預計強生在當前財年將發佈每股收益 10.58 美元。</p>
<h2>強生宣佈分紅</h2>
<p>該公司最近還宣佈了季度分紅，將於 9 月 9 日（星期二）支付。8 月 26 日（星期二）的登記投資者將獲得 1.30 美元的分紅。除息日為 8 月 26 日（星期二）。這代表着年化分紅為 5.20 美元，收益率為 2.9%。強生的分紅支付比率（DPR）目前為 55.61%。</p>
<h2>分析師評級上調和下調</h2>
<ul>
<li>擔心反彈消退？考慮這 3 只分紅股票</li>
</ul>
<p>幾位股票研究分析師最近對該公司發表了評論。Barclays 將強生的目標價從 165.00 美元上調至 176.00 美元，並在 7 月 17 日的研究報告中給予該公司 “持平” 評級。Guggenheim 在 7 月 17 日的研究報告中重申了 “中性” 評級，並將強生的目標價設定為 167.00 美元（此前為 164.00 美元）。加拿大皇家銀行將強生的目標價從 181.00 美元上調至 185.00 美元，並在 7 月 17 日的研究報告中給予該股票 “跑贏大盤” 評級。Leerink Partners 將強生的評級從 “跑贏大盤” 下調至 “市場表現”，並在 5 月 13 日的研究報告中將該股票的目標價從 169.00 美元下調至 153.00 美元。最後，Benchmark 在 4 月 24 日的研究報告中將強生的評級上調至 “強力買入”。兩位分析師對該股票給予強力買入評級，九位給予買入評級，九位對該公司的股票給予持有評級。根據 MarketBeat 的數據，該股票的平均評級為 “適度買入”，共識目標價為 176.29 美元。</p>
<p><strong>獲取我們最新的 JNJ 股票分析</strong></p>
<h2>關於強生</h2>
<p>（免費報告）</p>
<p>強生是一家控股公司，專注於醫療領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票，勝過強生</li>
<li>如何開始投資於便士股票</li>
<li>小型股，大潛力：你應該瞭解的 3 家科技顛覆者</li>
<li>電話會議和個人投資者</li>
<li>在財報失利後，沃爾瑪仍然是頂級消費品選擇</li>
<li>高分紅房地產投資信託：它們是理想的多元化方式嗎？</li>
<li>思科如何為投資者構建新的增長故事</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1000 美元在強生嗎？</h2>
<p>在考慮強生之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
<p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

強生

<p>Van Hulzen Asset Management LLC 在第一季度減少了對強生（NYSE: JNJ）22.5% 的持股，目前持有 118,842 股，價值約為 1970 萬美元。其他投資者，包括 Brighton Jones LLC 和 Hudson Value Partners LLC 也調整了他們的持倉。JNJ 股票開盤價為 178.90 美元，12 個月的價格區間為 140.68 美元至 180.61 美元。該公司報告第二季度每股收益為 2.77 美元，超出預期，並宣佈季度股息為 1.30 美元，收益率為 2.9%</p>

<p>Van Hulzen Asset Management LLC lessened its holdings in Johnson &amp; Johnson (NYSE:JNJ - Free Report) by 22.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities &amp; Exchange Commission. The firm owned 118,842 shares of the company's stock after selling 34,558 shares during the period. Johnson &amp; Johnson comprises approximately 1.8% of Van Hulzen Asset Management LLC's portfolio, making the stock its 12th biggest position. Van Hulzen Asset Management LLC's holdings in Johnson &amp; Johnson were worth $19,709,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Van Hulzen Asset Management LLC 在最近向證券交易委員會的披露中表示，在第一季度減少了對強生（NYSE:JNJ - 免費報告）22.5% 的持股。該公司在此期間出售了 34,558 股後，持有 118,842 股強生的股票。強生約佔 Van Hulzen Asset Management LLC 投資組合的 1.8%，使其成為該公司第 12 大持倉。截止最近一個季度末，Van Hulzen Asset Management LLC 在強生的持股價值為 19,709,000 美元。</p>
</div><ul>
<li>JNJ Stock Surge Signals Confidence in New Growth Path</li>
</ul>
<div class="lb-trans"><ul>
<li>JNJ 股票上漲表明對新增長路徑的信心</li>
</ul>
</div><p>Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Johnson &amp; Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Hudson Value Partners LLC increased its stake in shares of Johnson &amp; Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Burling Wealth Partners LLC acquired a new stake in Johnson &amp; Johnson during the fourth quarter valued at $3,908,000. Integrated Wealth Concepts LLC grew its stake in Johnson &amp; Johnson by 6.1% in the fourth quarter. Integrated Wealth Concepts LLC now owns 108,473 shares of the company's stock valued at $15,687,000 after purchasing an additional 6,247 shares in the last quarter. Finally, Empire Financial Management Company LLC increased its position in Johnson &amp; Johnson by 18.0% in the 4th quarter. Empire Financial Management Company LLC now owns 17,882 shares of the company's stock worth $2,586,000 after purchasing an additional 2,732 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他大型投資者最近也買賣了該公司的股票。Brighton Jones LLC 在第四季度將其在強生的股份增加了 13.9%。Brighton Jones LLC 現在持有 51,876 股強生的股票，價值 7,502,000 美元，此前在此期間又購買了 6,332 股。Hudson Value Partners LLC 在第四季度將其在強生的股份增加了 2.5%。Hudson Value Partners LLC 現在持有 41,403 股強生的股票，價值 5,648,000 美元，此前在上個季度又收購了 1,022 股。Burling Wealth Partners LLC 在第四季度收購了強生的新股份，價值為 3,908,000 美元。Integrated Wealth Concepts LLC 在第四季度將其在強生的股份增加了 6.1%。Integrated Wealth Concepts LLC 現在持有 108,473 股強生的股票，價值 15,687,000 美元，此前在上個季度又購買了 6,247 股。最後，Empire Financial Management Company LLC 在第四季度將其在強生的持倉增加了 18.0%。Empire Financial Management Company LLC 現在持有 17,882 股強生的股票，價值 2,586,000 美元，此前在上個季度又購買了 2,732 股。69.55% 的股票由機構投資者和對沖基金持有。</p>
</div><p>Get <strong>Johnson &amp; Johnson</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>強生</strong> 的提醒：</p>
</div><h2>Johnson &amp; Johnson Stock Performance</h2>
<div class="lb-trans"><h2>強生股票表現</h2>
</div><p>Shares of JNJ opened at $178.8990 on Friday. Johnson &amp; Johnson has a 12 month low of $140.68 and a 12 month high of $180.61. The company's fifty day moving average is $163.04 and its 200-day moving average is $159.05. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $430.85 billion, a price-to-earnings ratio of 19.13, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41.</p>
<div class="lb-trans"><p>強生的股票在週五開盤價為 178.8990 美元。強生的 12 個月低點為 140.68 美元，12 個月高點為 180.61 美元。該公司的 50 日移動平均線為 163.04 美元，200 日移動平均線為 159.05 美元。該公司的速動比率為 0.76，流動比率為 1.01，債務與股本比率為 0.50。該公司的市值為 4308.5 億美元，市盈率為 19.13，市盈增長比率為 2.28，貝塔值為 0.41。</p>
</div><ul>
<li>3 Big Dividend Plays With Strong Earnings to Back Them</li>
</ul>
<div class="lb-trans"><ul>
<li>3 大強勁收益的高分紅股票</li>
</ul>
</div><p>Johnson &amp; Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson &amp; Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the business posted $2.82 EPS. Johnson &amp; Johnson's revenue was up 5.8% compared to the same quarter last year. Johnson &amp; Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson &amp; Johnson will post 10.58 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>強生（NYSE:JNJ - 獲取免費報告）最近一次發佈財報是在 7 月 16 日，報告每股收益（EPS）為 2.77 美元，超出分析師一致預期的 2.68 美元，超出 0.09 美元。強生的淨利潤率為 25.00%，股本回報率為 32.49%。該公司在本季度的收入為 237.4 億美元，而分析師預期為 228.5 億美元。去年同期，該公司每股收益為 2.82 美元。強生的收入同比增長 5.8%。強生已將 2025 財年的指引設定為每股收益 10.800-10.900 美元。股票分析師預計強生在當前財年將發佈每股收益 10.58 美元。</p>
</div><h2>Johnson &amp; Johnson Announces Dividend</h2>
<div class="lb-trans"><h2>強生宣佈分紅</h2>
</div><p>The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson &amp; Johnson's dividend payout ratio (DPR) is presently 55.61%.</p>
<div class="lb-trans"><p>該公司最近還宣佈了季度分紅，將於 9 月 9 日（星期二）支付。8 月 26 日（星期二）的登記投資者將獲得 1.30 美元的分紅。除息日為 8 月 26 日（星期二）。這代表着年化分紅為 5.20 美元，收益率為 2.9%。強生的分紅支付比率（DPR）目前為 55.61%。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級上調和下調</h2>
</div><ul>
<li>Worried About a Fading Rally? Consider These 3 Dividend Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>擔心反彈消退？考慮這 3 只分紅股票</li>
</ul>
</div><p>Several equities research analysts recently commented on the company. Barclays boosted their price target on Johnson &amp; Johnson from $165.00 to $176.00 and gave the company an &#34;equal weight&#34; rating in a research note on Thursday, July 17th. Guggenheim restated a &#34;neutral&#34; rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson &amp; Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada increased their price target on shares of Johnson &amp; Johnson from $181.00 to $185.00 and gave the stock an &#34;outperform&#34; rating in a research note on Thursday, July 17th. Leerink Partners lowered shares of Johnson &amp; Johnson from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating and dropped their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Benchmark upgraded shares of Johnson &amp; Johnson to a &#34;strong-buy&#34; rating in a research note on Thursday, April 24th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $176.29.</p>
<div class="lb-trans"><p>幾位股票研究分析師最近對該公司發表了評論。Barclays 將強生的目標價從 165.00 美元上調至 176.00 美元，並在 7 月 17 日的研究報告中給予該公司 “持平” 評級。Guggenheim 在 7 月 17 日的研究報告中重申了 “中性” 評級，並將強生的目標價設定為 167.00 美元（此前為 164.00 美元）。加拿大皇家銀行將強生的目標價從 181.00 美元上調至 185.00 美元，並在 7 月 17 日的研究報告中給予該股票 “跑贏大盤” 評級。Leerink Partners 將強生的評級從 “跑贏大盤” 下調至 “市場表現”，並在 5 月 13 日的研究報告中將該股票的目標價從 169.00 美元下調至 153.00 美元。最後，Benchmark 在 4 月 24 日的研究報告中將強生的評級上調至 “強力買入”。兩位分析師對該股票給予強力買入評級，九位給予買入評級，九位對該公司的股票給予持有評級。根據 MarketBeat 的數據，該股票的平均評級為 “適度買入”，共識目標價為 176.29 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on JNJ</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 JNJ 股票分析</strong></p>
</div><h2>About Johnson &amp; Johnson</h2>
<div class="lb-trans"><h2>關於強生</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Johnson &amp; Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.</p>
<div class="lb-trans"><p>強生是一家控股公司，專注於醫療領域的產品研究、開發、製造和銷售。它通過創新藥物和醫療技術兩個部門運營。創新藥物部門專注於免疫學、傳染病、神經科學、腫瘤學、心血管和代謝以及肺動脈高壓。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Johnson &amp; Johnson</li>
<li>How to start investing in penny stocks</li>
<li>Small Cap, Big Potential: 3 Tech Disruptors You Should Know About</li>
<li>Conference Calls and Individual Investors</li>
<li>After Earnings Miss, Walmart Is Still a Top Consumer Staples Play</li>
<li>High Dividend REITs: Are They an Ideal Way to Diversify?</li>
<li>How Cisco Is Building a New Growth Story for Investors</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，勝過強生</li>
<li>如何開始投資於便士股票</li>
<li>小型股，大潛力：你應該瞭解的 3 家科技顛覆者</li>
<li>電話會議和個人投資者</li>
<li>在財報失利後，沃爾瑪仍然是頂級消費品選擇</li>
<li>高分紅房地產投資信託：它們是理想的多元化方式嗎？</li>
<li>思科如何為投資者構建新的增長故事</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUpOSg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=JNJ"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和來自 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Johnson &amp; Johnson Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在強生嗎？</h2>
</div><p>Before you consider Johnson &amp; Johnson, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮強生之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson &amp; Johnson wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而強生並不在名單上。</p>
</div><p>While Johnson &amp; Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然強生目前在分析師中獲得了中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Van Hulzen Asset Management LLC 減持了強生 $JNJ 的股份